-
Press Release: Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study
Sanofi’s Nexviazyme met all primary and secondary endpoints in infantile-onset Pompe disease phase 3 study Nexviazyme met its primary endpoint, participants alive and free of invasive ventilation, in treatment-naïve infants zero to six months of age in the Baby-COMET phase 3 study Sanofi intends to submit the data to support a regulatory application in the…
-
TraceLink Named Fortress Cybersecurity Awards Finalist for Enabling the Transformation to a Secure, Auditable Agentic Supply Chain Operating Model
OPUS Platform and OPUS Agents recognized for enabling no-code AI agents to operate as permissioned, traceable participants in regulated pharmaceutical supply chain operations Summary TraceLink has been named a finalist in the 2026 Fortress Cybersecurity Awards for OPUS and OPUS Agents. The recognition highlights TraceLink’s ability to support agentic supply chain operations in one of…
-
Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2 VIBRANT Trial at EAACI 2026
– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants – – Majority of verekitug-treated participants experienced clinically meaningful improvements across key secondary endpoints, including 72% in nasal congestion and 83% in CRSwNP total symptom score – WALTHAM, Mass., June 14, 2026 (GLOBE…
-
Exploratory Efficacy Data Suggests Further Study of Peanut Tolerance with Oral Mucosal Immunotherapy (OMIT)
NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) — Intrommune Therapeutics, Inc., a clinical-stage biotechnology company committed to developing a patient-friendly treatment platform for people with peanut and other food allergies, today announced the presentation of exploratory efficacy data from the Oral Mucosal Escalation Goal Assessment (OMEGA) Phase 1 safety trial at the 2026 Eastern Allergy…
Latest News
About the Author
We increase the awareness of millions of users through our news networks. We are one of the most trusted news networks in the world.